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Abstract
Background and aims Certolizumab pegol, a polyethylene
glycolated Fc-free Fab’ was efficacious and well tolerated
in patients with moderate-to-severe Crohn’s disease in a
previously reported randomized, placebo-controlled study.
In this paper, we report the effect of certolizumab pegol on
health-related quality of life (HRQoL).
Materials and methods Patients with moderate-to-severe
active Crohn’s disease (n=292) received subcutaneous
certolizumab pegol 100, 200, or 400 mg or placebo at
weeks 0, 4, and 8. A post hoc analysis of the intent-to-treat
population (290 patients with HRQoL data) assessed
HRQoL by evaluating patients’ responses to the self-
administered inflammatory bowel disease questionnaire
(IBDQ) at baseline and weeks 2, 4, 6, 8, 10, and 12.
Results Patients receiving certolizumab pegol 400 mg at
weeks 0, 4, and 8 demonstrated, via their IBDQ total score,
significantly (P≤0.05) greater improvement in HRQoL from
baseline to week 12 and at all other time points compared
with placebo. Moreover, HRQoL improved over time in
all certolizumab pegol groups, irrespective of baseline C-
reactive protein levels. Emotional well-being (IBDQ
Emotional Function domain) improved throughout the
study for patients receiving certolizumab pegol 400 mg.
This improvement was significantly (P≤0.05) greater than
for patients receiving placebo at all time points. In addition,
systemic symptoms (IBDQ Systemic Symptoms domain)
improved significantly more in patients receiving certolizu-
mabpegol400mgthaninthose receivingplaceboatweeks 4,
8, 10, and 12 (P≤0.05) and approached statistical signifi-
cance at week 2 (P=0.054).
Conclusion This analysis suggests that certolizumab pegol
400 mg improves HRQoL in patients with moderate-
to-severe Crohn’s disease.
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Crohn’s disease is a chronic relapsing and remitting,
inflammatory bowel disease (IBD) that has a significant
impact on health-related quality of life (HRQoL) [1, 2].
HRQoL has been recognized as an important health
outcome and has been defined in the medical setting as “a
concept encompassing a broad range of physical and
psychological characteristics and limitations which describe
an individual’s ability to function and derive satisfaction
from doing so” [3]. Crohn’s disease frequently begins in
early adulthood, causing a heavy disease burden in a
relatively young patient population. Consequently, many
patients will be affected for most of their adult life.
In Crohn’s disease, health status is affected as much by
psychosocial factors and functional status as by disease
activity [4]. For example, the need to wear an ostomy bag
may adversely affect self-image, and this has been reported
to be a common worry for patients with Crohn’s disease
[5]. Moreover, previous studies have demonstrated a high
correlation between disease severity, as measured by the
Crohn’s Disease Activity Index (CDAI) [6], and HRQoL,
as assessed using the Inflammatory Bowel Disease Ques-
tionnaire (IBDQ) [7, 8]. A large longitudinal study
prospectively assessed the HRQoL of patients with Crohn’s
disease over 1 year and determined influencing factors [9].
The following factors were associated with a negative
impact on overall HRQoL: female gender, tobacco use,
active Crohn’s disease, involvement of the colon, hospital-
ization, corticosteroid treatment, and surgery in the past
3 months (order does not indicate priority). These findings
were reflected in a survey of patients with a long-term
diagnosis of Crohn’s disease [10]. It is therefore important
to include improvement in HRQoL as a key therapeutic
goal in the treatment of patients with Crohn’s disease.
Conventional treatment options for Crohn’sd i s e a s e
include aminosalicylates, antibiotics, corticosteroids, immu-
nomodulators, and surgery. However, in some patients, the
disease can be refractory or unresponsive to certain
pharmacologic treatments. Furthermore, corticosteroids are
associated with a risk of dependency and potentially serious
side effects (e.g., diabetes, osteoporosis, moon face, and
acne), which are detrimental to a patient’s HRQoL and may
negatively affect self-esteem [11–13]. Such treatments
therefore require careful management. Additionally, it is
rarely possible to achieve long-term relief from Crohn’s
disease with a single surgical procedure, and as a result,
patients with Crohn’s disease fear surgery so much that
their HRQoL is reduced [14].
It is now well accepted that tumor necrosis factor α
(TNFα) plays a pivotal role in the underlying inflammatory
pathophysiology of Crohn’s disease [15]. Furthermore,
neutralization of TNFα has been shown to improve the
symptoms of this debilitating illness [13, 16]. Infliximab
has been shown to improve HRQoL, as measured by the
IBDQ and the Short-Form Health Survey (SF-36) [8, 17],
but the occurrence of infusion reactions along with the risk
of developing anti-infliximab antibodies, which can reduce
long-term efficacy [18], could negatively impact HRQoL
over time. Patients may feel that subcutaneous treatment
has advantages over treatments requiring infusion; a long
stay at the clinic may negatively impact a patient’s daily
life. This increased freedom in patient treatment manage-
ment may lead to improved treatment compliance with a
consequent impact on therapeutic outcomes. Thus, there is
a need for alternative long-term therapies for moderate-to-
severe Crohn’s disease that have minimal negative impact
on patients’ everyday life while also reducing the impact of
the disease on patients’ HRQoL [19].
Certolizumab pegol is the first polyethylene glycolated
(PEGylated) anti-TNFα antibody fragment (Fab’)t ob e
studied in Crohn’s disease. Unlike conventional anti-TNF
agents, certolizumab pegol lacks the crystallizable fragment
(Fc) region, thus potentially avoiding unwanted effects
[20]. PEGylation increases the plasma half-life and reduces
the frequency of dosing required. Certolizumab pegol is
administered by subcutaneous injection once every 4 weeks
(more frequent dosing may be used during an induction
phase). Certolizumab pegol 400 mg administered subcuta-
neously demonstrated efficacy and was well tolerated in
patients with moderate-to-severe active Crohn’s disease in
phases II [21] and III (PRECiSE 1 and PRECiSE 2 [22,
23]) studies. Certolizumab pegol has also demonstrated
clinical efficacy and good tolerability in patients with
rheumatoid arthritis [24, 25].
This is the first paper to report the effect of certolizumab
pegol, a monthly subcutaneous treatment, on the HRQoL of
patients with moderate-to-severe active Crohn’s disease in a
phase II placebo-controlled study [18]. HRQoL was
assessed using the IBDQ.
Materials and methods
Ethical conduct
This study was approved by the Independent Ethics
Committee/Institutional Review Board for each center
before initiation. It was conducted in accordance with the
International Conference for Harmonization Guidelines for
Good Clinical Practice and the declaration of Helsinki
(revised 1996).
Written informed consent was obtained from each patient
at screening before any study procedures were performed.
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Adult patients (age ≥18 years) with moderate-to-severe
active Crohn’s disease, as defined by a CDAI score of 220–
450 points during the week before the administration of the
first dose of study drug, were eligible for the study.
Exclusion criteria included suspected or diagnosed abscess,
a bowel perforation or evidence of non-inflammatory
obstruction in 6 months before screening, extensive bowel
resection, a functional colostomy or ileostomy, or a known
history of tuberculosis. Concomitant medication was
allowed, provided that doses were stable and could be
continued for the 12-week double-blind period and the
8-week follow-up.
Study design
This was a multicenter, randomized, double-blind, placebo-
controlled, 12-week study conducted at 58 international
centers between February 2001 and March 2002. An
8-week follow-up period allowed collection of additional
safety data. At screening, patients with moderate-
to-severe active Crohn’s disease were stratified according
to concomitant steroids, immunosuppressants, or long-term
anti-infectives. Eligible patients were randomized (1:1:1:1)
to receive certolizumab pegol (100, 200, or 400 mg)
or placebo (0.9% w/v saline) by subcutaneous injection
at weeks 0, 4, and 8 (Fig. 1). Before dosing, patients’
demography, medical history, and concomitant diseases
were recorded.
Outcomes
The primary endpoint of the study was the proportion of
patients achieving a clinical response [≥100-point decrease
in CDAI score or CDAI score ≤150 points (remission)] at
week 12. HRQoL was a secondary endpoint evaluated at
baseline (week 0, pre-injection) and at weeks 2, 4, 6, 8, 10,
and 12 using the 32-item self-administered IBDQ. The
IBDQ is a disease-specific HRQoL measure. The question-
naire assesses the four aspects of a patient’s life that are
affected by IBD: symptoms directly related to the primary
bowel symptoms, systemic symptoms, emotional function,
and social function [26]. The reliability, validity, and
responsiveness of the IBDQ have been demonstrated by
Guyatt et al. [26, 27] and Irvine et al. [7, 28]. The IBDQ is
completed using a 7-point Likert response for each
question. Total IBDQ scores range from 32 to 224, with a
higher score indicating better HRQoL. Remission is
generally indicated by a score of at least 170 points, and a
change of 16 points is regarded as clinically meaningful [7].
In addition to a total score, domain scores can be calculated
for the Bowel Symptoms, Systemic Symptoms, Emotional
Function, and Social Function domains. IBDQ measure-
ments were performed in parallel with determination of
CDAI score and serum concentrations of C-reactive protein
(CRP). Official IBDQ versions translated into Danish,
French, German, and Swedish were used. Our own trans-
lations were used for Russian, Serbian, and Afrikaans. To
assess whether our own translated versions of the IBDQ
provided a valid measure of HRQoL, we compared scores
of the translated versions with those of the official
translated versions and evaluated those scores in relation
to the patient’s CDAI scores. A sensitivity analysis was also
carried out to check for influence of specific item scores on
the resulting total scores. The results of these analyses
demonstrated that our own translated versions of the IBDQ
provided a valid measure of HRQoL, comparable to the
official, translated versions.
Statistical analysis
A sample size of 260 patients was calculated to give
approximately 83% power to detect a true difference
Fig. 1 Study design (showing
the total numbers of patients
recruited into each treatment
group)
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of the study, based on a placebo response rate of 12%. After
screening, patients were to be randomized in a 1:1:1:1 ratio
(65 patients to each of the four treatment groups).
Therefore, 195 patients were to receive certolizumab pegol
and 65 were to receive placebo.
Efficacy was assessed for the intent-to-treat (ITT)
population, which included all patients who received at
least one injection and had at least one efficacy measure-
ment after the first injection. Patients who terminated the
trial prematurely were advanced to the end-of-study visit.
The last observation carried forward method was used in
cases where data were missing.
Post hoc analyses of IBDQ total score and individual
domain scores were performed. These were purely explor-
atory in nature. Relationships between CDAI and IBDQ
global scores at week 12 were assessed for the ITT
population using Kendall’s tau coefficient, a measure of
the strength of dependence showing to what extent these
two variables move in the same direction. Changes from
baseline in IBDQ total score and individual domain scores
for each treatment group were formally compared with the
placebo group. Least-squares means, adjusted for stratum,
pooled country, and baseline IBDQ score, were compared
across treatment groups. Fisher’s exact test was used to
compare the proportion of patients who achieved remission
(defined as an IBDQ total score of ≥170 points) in each
active treatment group with that for the placebo group at
each week. The analyses were performed based on both the
overall ITT population and in the subgroup of patients with
elevated baseline CRP (≥10 mg/l). P values ≤0.05 were
considered to be statistically significant.
Results
The clinical efficacy and safety assessments of this phase II
dose-finding study have been reported in detail elsewhere
[21]. Because the 400 mg dose was identified as being the
most appropriate dose, this paper focuses on data for
patients receiving certolizumab pegol 400 mg.
Patients
In total, 372 patients were screened of whom 292 patients
were enrolled (CDAI score <220 points was the most
common reason for screening failure). Of these 292
patients, 291 were included in the ITT population used to
measure the efficacy endpoints according to CDAI scores
[1 patient (400 mg group) was excluded because of missing
efficacy data]. Baseline IBDQ scores were not obtained for
one patient in the certolizumab pegol 100 mg treatment
group. The ITT analyses for the HRQoL evaluations
therefore included data for 290 patients. Seventy-five
patients (25.7%) withdrew from the study by week 12.
The majority of withdrawals were a consequence of lack of
improvement/disease progression.
Baseline CRP measurements were obtained for 290 of
the 291 patients in the ITT population. Elevated baseline
CRP levels (≥10 mg/l) were recorded for 119 patients
(41.0%). One of these patients was the patient in the
certolizumab pegol 100 mg treatment group who was
excluded from analyses as a result of baseline IBDQ scores
not being obtained. The subgroup analyses of IBDQ by
baseline CRP status were therefore performed on data from
118 patients with an elevated baseline CRP concentration.
The four treatment groups were generally well matched
in terms of demographic and clinical characteristics
(including baseline IBDQ total score and concomitant
medication profile; Table 1). In the ITT population, 21.6%
of patients had received previous anti-TNFα therapy, and
15.5% had concomitant medication with both immuno-
modulators and steroids.
Clinical response
The onset of effect (clinical response) of certolizumab
pegol was evident at week 2, when certolizumab pegol
treatment produced a statistically significant improvement
in CDAI score compared with placebo (certolizumab pegol
400 mg 33.3% vs placebo 15.1%; P=0.010). Clinical
response rates were highest in the certolizumab pegol
400 mg group at all time points, with maximal response
at week 10 (certolizumab pegol 400 mg 52.8% vs placebo
30.1%; P=0.006) [21]. Lower CDAI score (representing
lower disease severity) was associated with a higher IBDQ
global score (representing better HRQoL), as reflected by a
high negative Kendall’st a uv a l u e( −0.48; P<0.0001)
Clinical response was observed irrespective of baseline
CRP level.
Improvement in HRQoL
Patients demonstrated HRQoL improvements from base-
line, as measured by change in IBDQ total score, by the
first assessment point, week 2 [certolizumab pegol 100 mg,
16.6 points; certolizumab pegol 200 mg, 21.8 points (P≤
0.05 vs placebo); certolizumab pegol 400 mg, 22.8 points
(P≤0.05 vs placebo); placebo, 10.6 points] (Fig. 2).
Patients receiving certolizumab pegol 400 mg experienced
statistically significantly greater improvements from base-
line in IBDQ total score at all time points (P≤0.05)
compared with those receiving placebo. The greatest
increase in IBDQ total score was recorded at week 10
(certolizumab pegol 400 mg 32.2 points vs 18.6 points
for placebo; P≤0.05). Approximately half of the patients
292 Int J Colorectal Dis (2008) 23:289–296treated with certolizumab pegol 400 mg demonstrated
clinically meaningful improvements in IBDQ total score
(≥16-point increase) at week 2 (52.8%) and at week 12
(66.7%).
As early as week 2, patients receiving certolizumab
pegol 400 mg demonstrated statistically significant
improvements in the Bowel Symptoms and Emotional
Function domains of the IBDQ relative to placebo
(Fig. 3). Improvement in the Systemic Symptoms domain
score approached statistical significance at week 2 (P=
0.054). These improvements were generally dose-related
(Figs. 3a−d). Interestingly, patients in the certolizumab
pegol 200 mg group achieved statistically significantly
greater improvements than those receiving placebo in
IBDQ total score and all four IBDQ domains at week 2
(Figs. 2 and 3a–d).
Emotional Function and Systemic Symptoms were the
domains that patients reported as being most improved by
certolizumab pegol treatment. At every assessment, patients
receiving certolizumab pegol 400 mg showed statistically
significantly (P≤0.05) greater improvements in Emotional
Function domain scores than those receiving placebo
(Fig. 3c). They also demonstrated statistically significantly
greater improvements in Systemic Symptoms domain
scores than those receiving placebo at weeks 4, 8, 10, and
12 (Fig. 3b). The improvements patients experienced in
Fig. 2 Mean change from base-
line in Inflammatory Bowel
Disease Questionnaire (IBDQ)
total score during 12 weeks’
subcutaneous treatment with
either certolizumab pegol or
placebo in patients with
moderate-to-severe Crohn’s
disease (intent-to-treat
population); least-squares
means (adjusted for stratum,
pooled country, and baseline
score)
Table 1 Baseline demographic and clinical characteristics (intent to treat population used to measure efficacy endpoints according to Crohn’s
Disease Activity Index scores)
Placebo(n=73) Certolizumab pegol
100 mg (n=74) 200 mg (n=72) 400 mg (n=72)
Mean CDAI score (range) 291.5 (206–448) 299.2 (194–520) 310.7 (184–446) 304.5 (204–461)
Mean IBDQ score (range)
a 122.9 (61–190) 132.2 (66–189)
b 122.9 (74–189) 126.5 (71–177)
Geometric mean plasma CRP, mg/l (range) 7.268 (0.27–86.10) 6.231 (0.15–141.00)
b 6.475 (0.17–127.00) 7.738 (0.35–128.28)
CRP≥10 mg/l, n (%) 28 (38.4) 31 (42.5)
b 28 (38.9) 32 (44.4)
Concomitant medications, n (%)
Aminosalicylates 29 (39.7) 37 (50.0) 32 (44.4) 28 (38.9)
Anti-infectives 7 (9.6) 6 (8.1) 7 (9.7) 6 (8.3)
Antidiarrheals 10 (13.7) 19 (25.7) 16 (22.2) 12 (16.7)
Steroids 29 (39.7) 24 (32.4) 29 (40.3) 22 (30.6)
Codeine and derivatives 6 (8.2) 5 (6.8) 5 (6.9) 2 (2.8)
Immunomodulators
Azathioprine 17 (23.3) 13 (17.6) 23 (31.9) 22 (30.6)
6-Mercaptopurine 4 (5.5) 9 (12.2) 2 (2.8) 2 (2.8)
Methotrexate 5 (6.8) 4 (5.4) 4 (5.6) 3 (4.2)
CDAI Crohn’s Disease Activity Index; CRP C-reactive protein; IBDQ Inflammatory Bowel Disease Questionnaire; n number of patients
aMaximum score is 224 points.
bData missing for one patient.
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significance (P=0.054) at week 4 (Fig. 3d).
The remission rate in the certolizumab pegol 400 mg
group was highest at week 10. This was statistically
significantly greater than in the placebo group (Table 2).
The proportion of patients achieving remission in the
certolizumab pegol 400 mg group was also statistically
significantly greater than in the placebo group at weeks 6,
8, and 12. The subgroup of patients with elevated CRP
showed similar improvements in IBDQ scores to those
observed in the ITT population.
Discussion
Patients with Crohn’s disease often have poor HRQoL [29],
with disease-related concerns, such as worry about needing
surgery, being the main causal factor [10]. It therefore
Fig. 3 Mean change from baseline in Inflammatory Bowel
Disease Questionnaire (IBDQ) domain scores during 12 weeks
subcutaneous treatment with either certolizumab pegol or placebo in
patients with moderate-to-severe Crohn’s disease (intent-to-treat
population); least-squares means (adjusted for stratum, pooled
country, and baseline score): a Bowel Symptoms domain, b Systemic
Symptoms domain, c Emotional Function domain, and d Social
Function domain
Table 2 Proportion of patients achieving remission defined by Inflammatory Bowel Disease Questionnaire total score (≥170 points)
Patients (%), intent-to-treat population (n=290)
Week Placebo (n=73) Certolizumab pegol
100 mg (n=73) 200 mg (n=72) 400 mg (n=72)
2 17.8 32.9 19.4 27.8
4 19.2 37.0
a* 26.4 33.3
6 17.8 35.6* 30.6 38.9*
8 21.9 35.6 29.2 38.9*
10 27.4 43.8 36.1 47.2*
12 23.3 38.4 23.6 38.9*
aThe higher remission rate at week 2 in the certolizumab pegol 100 mg group compared with higher-dose groups may reflect the slightly higher
mean Inflammatory Bowel Disease Questionnaire (IBDQ) score at baseline in this group. However, certolizumab pegol 400 mg resulted in the
greatest mean change in IBDQ at all time points.
*P≤0.05 vs placebo
294 Int J Colorectal Dis (2008) 23:289–296follows that treatments relieving the symptoms of Crohn’s
disease and/or reducing the risk of surgery should improve
HRQoL in patients with Crohn’s disease.
Certolizumab pegol administered subcutaneously every
4 weeks is a rapid and clinically effective treatment of
moderate-to-severe Crohn’s disease with the 400 mg dose
(highest dose tested) inducing the highest response rates
[21, 22, 23]. This analysis indicates that such clinical
findings are accompanied by improvements in HRQoL.
Certolizumab pegol 400 mg appears to exert a rapid,
consistently positive effect on HRQoL in patients with
moderate-to-severe Crohn’s disease. Patients who received
certolizumab pegol 400 mg demonstrated statistically sig-
nificantly greater improvements in IBDQ total score than
those in the placebo group as early as week 2 and at all
subsequent time points. As a reflection of the lower baseline
IBDQ scores in the 400 mg group, patients in this group
experienced the greatest improvement, despite the remission
rate (which is the proportion of patients reaching a pre-
defined score) being higher in the 100 mg group. Improve-
ments in HRQoL were not dependent on baseline CRP level.
Higher baseline CRP concentration was associated with
greater improvement in clinical variables in this phase II
study [21], but such a relationship has not been evident in
phase III studies [30]. In addition, patients receiving
certolizumab pegol 200 mg showed a statistically signifi-
cantly greater change from baseline in IBDQ total score
than those receiving placebo at weeks 2 and 4. Collectively,
these findings suggest that certolizumab pegol has an early
treatment effect in patients with moderate-to-severe Crohn’s
disease. The benefits of certolizumab pegol on HRQoL
were also apparent in the phase III studies [22, 23, 31, 32].
Improvements in emotional well-being (e.g. depression,
anxiety, irritability, and anger resulting from bowel prob-
lems) and systemic symptom domains were particularly
marked with certolizumab pegol treatment. It appears that
the improvements in these two domains of the IBDQ are
largely responsible for the reported beneficial effect of
certolizumab pegol on HRQoL. Overall, these findings
suggest that certolizumab pegol alleviates the psychological
symptoms associated with Crohn’s disease and improves
a patient’s general well-being, in addition to providing
clinical benefits in terms of CDAI response.
HRQoL provides an integral picture of the interactions
between a patient’s disease, their treatment, and quality of
life—positive effects resulting from the efficacy of a
treatment and negative effects caused by adverse events
are evaluated. Few trials have examined the effects of
conventional agents upon HRQoL in patients with Crohn’s
disease. While corticosteroids are effective in controlling
acute Crohn’s disease and are reported to improve IBDQ
scores [33], the potentially serious adverse events asso-
ciated with corticosteroids may negate any positive effects
on HRQoL gained through control of symptoms. Addition-
ally, corticosteroids are not suitable for maintenance
treatment. Improvements in HRQoL have been observed
with methotrexate treatment in a large, randomized, double-
blind, placebo-controlled study [34]. However, 17% of
patients (16/94) receiving methotrexate were withdrawn
from the study because of adverse events compared with
2% of placebo-treated patients (1/47).
The improvements in HRQoL observed with certolizumab
pegol in this study appear to be similar to those reported in
patients with Crohn’s disease after treatment with infliximab
[8, 17, 35]. Similarly, natalizumab has been shown to
improve HRQoL in patients with Crohn’s disease [36].
Given the detrimental effects of Crohn’s disease on
physical and psychosocial functioning, additional research
is needed to assess the impact of currently available and
newer therapies on HRQoL. Although HRQoL was
evaluated using the self-administered IBDQ, which has
proved to be a valid and reliable disease-specific instrument
for determining health status in patients with Crohn’s
disease [7], the analyses presented in this paper were purely
exploratory in nature, and firm conclusions cannot be
drawn from the results described. However, clinical benefit
was also accompanied by improved HRQoL in the phase III
studies [22, 23, 31, 32]. Further benefits may be gained
through the good tolerability of certolizumab pegol [37]
and convenience of subcutaneous dosing with certolizumab
pegol once every 4 weeks.
Conclusions
This study demonstrates that the clinical efficacy of
certolizumab pegol in patients with moderate-to-severe
Crohn’s disease, which is evident within 2 weeks of injection,
is paralleled by improvements in HRQoL. The benefits of
certolizumab pegol were most pronounced at the highest dose
tested (400 g). Improvements in emotional well-being and
systemic symptoms appear to be largely responsible for the
observed beneficial effect of certolizumab pegol on HRQoL.
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